Breaking News Instant updates and real-time market news.

BLUE

Bluebird Bio

$149.90

-6.85 (-4.37%)

, SEAS

SeaWorld

$21.12

-0.36 (-1.68%)

08:58
08/06/18
08/06
08:58
08/06/18
08:58

Fly Intel: Pre-market Movers

HIGHER: Bluebird Bio (BLUE), up 5% after after announcing a collaboration with Regeneron Pharmaceuticals (REGN) in the pursuit of immune cell therapies for cancer treatment... Intercept (ICPT), up 7% after Goldman Sachs analyst Salveen Richter double upgraded the stock to Buy from Sell and raised his price target for the shares to $157 from $46. The analyst says Ocaliva in fatty liver disease nonalcoholic steatohepatitis is the crux of Intercept's value proposition and that he's positive into the Phase 3 Regenerate interim readout in the first half of 2019... Antares Pharma (ATRS), up 8.5% after entering into an agreement with Pfizer (PFE) to develop a combination drug device rescue pen... UP AFTER EARNINGS: SeaWorld (SEAS), up 15%. DOWN AFTER EARNINGS: HSBC (HSBC), down 1.5%... Sempra Energy (SRE), down 3%. ALSO LOWER: Praxair (PX), down 6% after Linde (LNEGY) announced late Friday that discussions with various antitrust authorities have resulted in further indications that merger clearances for the compannies' proposed combination could be subject to requirements "more onerous than previously expected."... Acadia (ACAD), down 3% after Piper Jaffray analyst Danielle Brill downgraded the stock to Neutral and cut her firm's price target for the shares to $19 from $61 after taking over coverage of the name. The recent negative headlines related to potential Nuplazid safety issues will continue to weigh on sales and the shares for the foreseeable future, Brill tells investors.

BLUE

Bluebird Bio

$149.90

-6.85 (-4.37%)

SEAS

SeaWorld

$21.12

-0.36 (-1.68%)

ICPT

Intercept

$97.33

-3.88 (-3.83%)

ATRS

Antares Pharma

$2.60

-0.04 (-1.52%)

HSBC

HSBC

$47.18

0.585 (1.26%)

PX

Bought by LIN

$164.22

1.065 (0.65%)

SRE

Sempra Energy

$116.74

0.7 (0.60%)

ACAD

Acadia

$15.23

-0.26 (-1.68%)

  • 06

    Aug

  • 06

    Aug

  • 07

    Aug

  • 08

    Aug

  • 14

    Aug

  • 30

    Aug

  • 31

    Aug

  • 29

    Sep

BLUE Bluebird Bio
$149.90

-6.85 (-4.37%)

08/02/18
PIPR
08/02/18
NO CHANGE
PIPR
Overweight
Piper Jaffray says 'exciting period' ahead for Bluebird Bio
Piper Jaffray analyst Tyler Van Buren said Bluebird Bio made substantial progress in Q2 and reported what he believes were very positive datasets across its key development programs. The analyst, who contends that Bluebird is "entering an exciting period of time," recommends that investors own the shares to realize the additional value that will be generated from LentiGlobin, bb2121(7), and Lenti-D as the company has the potential for its first three product approvals over the period of 2019-2020. Van Buren maintains an Overweight rating on Bluebird Bio shares.
07/30/18
MAXM
07/30/18
NO CHANGE
Target $163
MAXM
Hold
Bluebird Bio price target lowered to $163 from $200 at Maxim
Maxim analyst Jason McCarthy lowered his price target on Bluebird Bio to $163 after the company's announced capital raise, expecting about $630M in proceeds. The analyst also keeps his Hold rating, saying that while the accelerated EMA assessment on LentiGlobin could reduce the review period to 150 days from 210 days, the company has "only incremental catalysts" in the short term.
06/19/18
EVER
06/19/18
UPGRADE
Target $230
EVER
Outperform
Bluebird Bio upgraded to Outperform with $230 price target at Evercore ISI
As previously reported, Evercore ISI analyst Josh Schimmer upgraded Bluebird Bio (BLUE) to Outperform from In Line, stating that its recent updates for LentiGlobin for sickle cell disease and for its myeloma CAR-T program partnered with Celgene (CELG) have increased his view of the prospects for commercial success for both programs. While competitor CAR-T updates may show that bb2121 is not particularly differentiated, it will have a key first-mover advantage and strong commercial partner, Schimmer tells investors. Schimmer raised his price target on Bluebird shares to $230 from $175.
06/19/18
EVER
06/19/18
UPGRADE
EVER
Outperform
Bluebird Bio upgraded to Outperform from In Line at Evercore ISI
SEAS SeaWorld
$21.12

-0.36 (-1.68%)

07/09/18
WELS
07/09/18
DOWNGRADE
WELS
Market Perform
Six Flags downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded Six Flags (SIX) to Market Perform from Outperform, citing valuation, negative seasonal trading patterns and incremental FX related UK/Brazilian headwinds, despite ongoing favorable consumer fundamentals and the key Q3 just starting. Wells Fargo also downgraded SeaWorld (SEAS) to Market Perform this morning.
07/09/18
07/09/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Procter & Gamble (PG) downgraded to Hold from Buy at Jefferies with analyst Kevin Grundy saying slowing market growth, volatility in emerging markets, U.S. retail difficulties, the stronger U.S. dollar and "pricing challenges" should drive estimates lower. 2. SeaWorld (SEAS) and Six Flags (SIX) were downgraded to Market Perform from Outperform at Wells Fargo. 3. Walgreens Boots Alliance (WBA) downgraded to Neutral from Buy at Citi with analyst Ralph Giacobbe saying he finds it difficult to argue for "meaningful multiple expansion" given headwinds from industry pressures and a dynamic and changing backdrop. 4. Flowers Foods (FLO) downgraded to Hold from Buy at Vertical Group. 5. Wayfair (W) downgraded to Market Perform from Outperform with the firm citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/09/18
07/09/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GAMESTOP STARTED WITH A BUY: Jefferies analyst Stephanie Wissink started GameStop (GME) with a Buy rating and $18 price target. Her contrarian view on the stock is that under potential new leadership with a well defined vision and execution plan, the stock's valuation, which she feels is "overlooked and overly discounted," could improve. GameStop is higher by 2.5% in midday trading. PIPER SEES CISCO LOSING SECURITY SHARE TO PALO ALTO: Piper Jaffray analyst James Fish says his firm's recent channel survey work across networking and security were weaker than he's seen in past calendar quarters for Cisco Systems (CSCO). Cisco's Security survey results were "especially weak," implying Palo Alto Networks (PANW) is taking market share, the analyst said, although the former remains his top networking pick. He kept an Overweight rating on Cisco shares, which were down almost 1% in midday trading. JEFFERIES DOWNGRADES P&G: Jefferies analyst Kevin Grundy downgraded Procter & Gamble (PG) to Hold from Buy and lowered his price target for the shares to $79 from $83. Slowing market growth, volatility in emerging markets, U.S. retail difficulties, the stronger U.S. dollar and "pricing challenges" should drive estimates lower, Grundy told investors in a research note titled "Tide Unlikely to Turn: Downgrade to Hold as Bull Thesis Wanes." Grundy said he preferred shares of Church & Dwight (CHD) and Energizer (ENR) for exposure to the Home and Personal Care space. TRADE DESK STARTED WITH A SELL: Pivotal Research analyst Brian Wieser initiated Trade Desk (TTD) with a Sell rating and $58 price target, stating that he believes the company can grow rapidly this year but should then see its growth decelerate. He believes its growth will plateau at a size smaller than Criteo's (CRTO), on which Wieser also initiated coverage this morning with a Buy rating. WELLS FARGO DOWNGRADES TWO THEME PARKS: Wells Fargo analyst Timothy Conder downgraded both SeaWorld (SEAS) and Six Flags (SIX) to Market Perform from Outperform, citing valuation, negative seasonal trading patterns, and weather impact, despite ongoing favorable consumer fundamentals and the key Q3 just starting. SeaWorld is trading down 1.3%, while Six Flags is down 1.7% at midday.
07/18/18
STFL
07/18/18
NO CHANGE
Target $27
STFL
Buy
SeaWorld shorts may be 'chased' by earnings report catalysts, says Stifel
Stifel analyst Steven Wieczynski said he expects SeaWorld's Q2 earnings announcement to include four potential catalysts, which he ranks from most likely to least likely as an EBITDA beat, John Reilly being named permanent CEO, a long-range EBITDA target being established, and refinancing of loans due May 2020 being announced. While seeing all four is "somewhat of a longshot," he has a high degree of confidence in the first three and would expect to see "additional shorts chased from the name" if the catalysts he is calling for are in the report. Wieczynski raised his price target on SeaWorld shares ahead of the report to $27 from $25 and keeps a Buy rating on the name.
ICPT Intercept
$97.33

-3.88 (-3.83%)

06/28/18
RAJA
06/28/18
INITIATION
Target $122
RAJA
Strong Buy
Intercept initiated with a Strong Buy at Raymond James
Raymond James analyst Steven Seedhouse initiated Intercept with a Strong Buy and $122 price target.
08/06/18
GSCO
08/06/18
UPGRADE
Target $157
GSCO
Buy
Intercept upgraded to Buy from Sell at Goldman Sachs
Goldman Sachs analyst Salveen Richter double upgraded Intercept Pharmaceuticals (ICPT) to Buy from Sell and raised his price target for the shares to $157 from $46. The stock closed Friday down 3.5%, or $3.57, to $97.26. The analyst says Ocaliva in fatty liver disease nonalcoholic steatohepatitis is the crux of Intercept's value proposition and that he's positive into the Phase 3 Regenerate interim readout in the first half of 2019. Richter this morning also downgraded Madrigal Pharmaceuticals (MDGL) to Neutral from Buy. He believes, however, that Madrigal's MGL-3196 is a "best-in-industry, next-generation" drug for nonalcoholic steatohepatitis. The analyst expects Intercept's Ocaliva will achieve one or both of the Phase 3 co-primary endpoints of NASH resolution and fibrosis improvement. He sees share upside of 60%-plus as the first half of 2019 catalyst approaches. Intercept should benefit from Ocaliva's global first-mover advantage in NASH, Richter tells investors in a research note. Goldman estimates peak global sales of NASH drugs to be $3.7B.
08/06/18
WEDB
08/06/18
NO CHANGE
Target $217
WEDB
Outperform
Intercept price target raised to $217 from $203 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for Intercept to $217 from $203 after the company reported "strong" Q2 earnings. The analyst reiterates an Outperform rating on the shares.
08/03/18
LDLW
08/03/18
DOWNGRADE
LDLW
Hold
Intercept downgraded to Hold from Buy at Laidlaw
Laidlaw analyst Francois Brisebois downgraded Intercept to Hold from Buy with a $95 price target following the Q2 report citing valuation.
ATRS Antares Pharma
$2.60

-0.04 (-1.52%)

05/08/18
HCWC
05/08/18
NO CHANGE
Target $4
HCWC
Buy
Antares target raised to $4 on higher Xyosted confidence at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat said that Antares Pharma reported "solid" Q1 results but "most importantly...finally explicitly confirmed a key aspect of the Xyosted filing," specifically that the company already conducted an ambulatory blood pressure monitoring study as part of the supplemental safety study ahead of the NDA submission. That fact, along with Antares' ability to re-submit the NDA just a week after receiving the minutes from the FDA Type-A meeting, increases his confidence in Xyosted approval coming in 2018, Livnat said. He raised his view of Xyosted's probability of success to 70% from 40% and increased his price target to $4 from $3.50 on Antares shares. Livnat keeps a Buy rating on the stock.
10/23/17
JANY
10/23/17
NO CHANGE
JANY
Neutral
Antares CRL doesn't raise issues for Amag Pharmaceuticals, says Janney Capital
Janney Capital analyst Ken Trbovich noted that the FDA complete response letter issued to Antares (ATRS) for Xyosted did not pertain to the Quickshot subcutaneous autoinjector, which raises his confidence the FDA will not identify such issues as a short coming of the sNDA for Amag Pharmaceuticals' (AMAG) Makena SQ. However, he keeps a Neutral rating on Amag shares, noting that the primary uncertainty for the sNDA for Makena SQ is the fact that its peak plasma levels is higher than the upper bound the FDA uses to define bioequivalence.
10/23/17
RAJA
10/23/17
NO CHANGE
Target $3.4
RAJA
Strong Buy
Antares Pharma maintained as a Strong Buy at Raymond James
Raymond James analyst Elliot Wilbur said the FDA's CRL on Antares Pharma (ATRS) XYOSTED was an unexpected and significant setback, but weakness in shares since the October disclosure effectively prices XYOSTED at zero, and substantially undervalues other development programs, especially ANDA products with Teva (TEVA). Wilbur is not writing-off XYSTED yet and is pushing out an expected launch to 2H19 from early 2018 previously, and is now discounting the probability of success at 50% versus 100% prior to the CRL. The analyst maintains asset values for Antares' non-XYOSTED assets are worth $2.50 per share using a sum-of-the-parts valuation and adjusted his price target to $3.40 from $4.20 on shares. Wilbur maintains a Strong Buy rating on Antares
10/23/17
MSCO
10/23/17
NO CHANGE
Target $26
MSCO
Overweight
Antares CRL should have limited read through to Amag, says Morgan Stanley
After Antares Pharma (ATRS) announced that it has received a FDA complete response letter about the new drug application for Xyosted due to two deficiencies related to clinical data, Morgan Stanley analyst Thomas Smith said the CRL should have limited read through to Amag Pharmaceuticals (AMAG), which has partnered with Antares for technology being used in subcutaneous Makena. The CRL is not related to the device or manufacturing, noted Smith, who adds that investor relief over the minimal Makena read through could lead to a rally in Amag shares following the recent weakness. He keeps 60% probability of success for Makena SC and maintains an Overweight rating on Amag shares.
HSBC HSBC
$47.18

0.585 (1.26%)

07/10/18
JPMS
07/10/18
UPGRADE
JPMS
Overweight
HSBC upgraded to Overweight from Neutral at JPMorgan
07/11/18
JPMS
07/11/18
UPGRADE
JPMS
Overweight
JPMorgan sees value in HSBC after pullback, upgrades to Overweight
JPMorgan analyst Katherine Lei last night upgraded HSBC to Overweight from Neutral and raised her price target for the shares to HKD 92 from HKD 88. Despite stable asset quality and an improving net interest margin outlook, HSBC's share price corrected 14% from the peak in January, Lei tells investors in a research note. The analyst sees value in the shares at current levels.
07/11/18
07/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Myriad Genetics (MYGN) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Steve Beuchaw saying the core HCT business is showing more durability, with volumes returning to growth and price declines slowing, while the acquisitions of Assurex and Counsyl are diversifying the company into higher growth and improving average selling price testing markets. 2. HSBC (HSBC) upgraded to Overweight from Neutral at JPMorgan with analyst Katherine Lei saying despite stable asset quality and an improving net interest margin outlook, HSBC's share price corrected 14% from the peak in January. 3. Conn's (CONN) upgraded to Buy from Hold at Stifel with analyst John Baugh saying he left a recent meeting with management feeling confident that the recent indications of improvement in the credit segment should continue. 4. TripAdvisor (TRIP) upgraded to Overweight from Equal Weight at Barclays with analyst Deepak Mathivanan saying the company's fundamentals "are starting to turn around." 5. Imperial Oil (IMO) upgraded to Equal Weight from Underweight at Barclays. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/07/18
LYON
05/07/18
UPGRADE
LYON
Buy
HSBC upgraded to Buy from Outperform at CLSA
PX Bought by LIN
$164.22

1.065 (0.65%)

05/30/18
JPMS
05/30/18
UPGRADE
JPMS
Overweight
Linde upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Alberto Rueda upgraded Linde (LNEGY) to Overweight and raised his price target for the shares to EUR 217 from EUR 212. The analyst has increased confidence in "substantial" upside from the proposed merger with Praxair (PX).
03/27/18
BMOC
03/27/18
INITIATION
Target $159
BMOC
Market Perform
Praxair initiated with a Market Perform at BMO Capital
BMO Capital analyst John McNulty started Praxair with a Market Perform rating and $159 price target.
03/19/18
SBSH
03/19/18
NO CHANGE
SBSH
Buy
Praxair shares could fall 10%-15% initially if deal fails, says Citi
Citi analyst P.J. Juvekar believes Praxair (PX) shares could initially fall 10%-15% if the merger with Linde were to fail due to regulatory restrictions. The analyst, however, thinks shares should eventually trade based on its standalone merits, which he remains positive on. He recommends playing the deal through Praxair over Linde. Juvekar keeps a Buy rating on the shares.
08/06/18
JEFF
08/06/18
NO CHANGE
Target $194
JEFF
Buy
Jefferies still sees over 85% chance of Linde, Praxair merger
Jefferies analyst Laurence Alexander believes additional concerns from the Federal Trade Commission will precipitate additional asset sales at "relatively low multiples" in order to close merger between Linde (LNEGY) and Praxair (PX). The analyst estimates a 35c earnings per share buffer for Praxair on 2020 estimates before "defending a near-term value dilutive deal becomes an issue." Pending more detail, Alexander pegs the deal probability at greater than 85%. In the event of the deal failing, the analyst would expect Praxair management to "immediately announce a plan to ratchet up buybacks." He keeps a Buy rating on Praxair with a $194 price target.
SRE Sempra Energy
$116.74

0.7 (0.60%)

07/30/18
JPMS
07/30/18
NO CHANGE
Target $110
JPMS
Neutral
Sempra Energy LNG business worth $16 per share, says JPMorgan
JPMorgan analyst Christopher Turnure estimates "only" a $16 per share value for Sempra Energy's LNG business. In a research note titled "Checking the Math on LNG Enthusiasm; Business Worth $16/shr," the analyst keeps a Neutral rating on Sempra. He believes the company's "development upside optionality" is priced into the stock at current levels. Turnure raised his price target for the stock to $110 from $108.
06/12/18
WELS
06/12/18
DOWNGRADE
WELS
Market Perform
Sempra Energy downgraded to Market Perform from Outperform at Wells Fargo
06/12/18
06/12/18
DOWNGRADE
Target $123

Market Perform
Sempra Energy downgraded to Market Perform at Wells Fargo
As previously reported, Wells Fargo analyst Sarah Akers downgraded Sempra Energy to Market Perform from Outperform, citing balanced risk/reward following activist-driven pop. While the analyst sees opportunities to unlock value via effective capital allocation and new growth ventures, she would not argue for multiple expansion at this point given below average credit metrics and ongoing risks. Akers also raised her price target on the stock to $123 from $118.
07/09/18
ARGS
07/09/18
NO CHANGE
Target $130
ARGS
Buy
Sempra Energy price target raised to $130 from $119 at Argus
Argus analyst Jacob Kilstein raised his price target on Sempra Energy to $130 and kept his Buy rating, citing the management's favorable guidance at its June 28th invest meeting. The analyst is also positive on the efforts made by activist investors Elliott Management and Bluescape Resources to increase profitability as they push for Sempra Energy to sells its international businesses and separate the company into a utility-focused entity and a natural gas infrastructure one. Kilstein further points to the management's estimates of the purchased Oncor majority stake to increase earnings by 10c-20c over the next four years.
ACAD Acadia
$15.23

-0.26 (-1.68%)

08/06/18
PIPR
08/06/18
DOWNGRADE
Target $19
PIPR
Neutral
Acadia downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Danielle Brill downgraded Acadia Pharmaceuticals to Neutral and cut her firm's price target for the shares to $19 from $61 after taking over coverage of the name. The stock closed Friday down 27c to $15.22. The recent negative headlines related to potential Nuplazid safety issues will continue to weigh on sales and the shares for the foreseeable future, Brill tells investors in a research note. Further, the analyst does not have a high level of conviction for positive data from Acadia's near-term catalysts, namely the Phase 2 major depressive disorder data in September and the Phase 2 negative schizophrenia symptoms readout in the first half of 2019.
04/26/18
JPMS
04/26/18
NO CHANGE
JPMS
Overweight
JPMorgan still sees low risk of Acadia drug being pulled from market
JPMorgan analyst Cory Kasimov continues to see a low, "but not zero," risk of Acadia Pharmaceuticals' Nuplazid being pulled from the market. Yesterday's CNN report is "mostly noise" and "nothing new," Kasimov told investors last night in a research note. The analyst, however, says he can appreciate the impact of the FDA Commissioner indicating he would "take another look" at the drug's safety profile. Kasimov predicates his views on the formal FDA review and the agency's initial statement that Nuplazid's safety profile is consistent with the label, as well as additional commentary he received yesterday from management. The analyst views yesterday's pullback in shares of Acadia as "fundamentally unjustified based on current information." He kept an Overweight rating on the stock. Shares of Acadia are up 5% to $15.95 in early trading.
04/10/18
COWN
04/10/18
NO CHANGE
Target $50
COWN
Outperform
Acadia pimavanserin concerns a reason for caution, says Cowen
Cowen analyst Ritu Baral noted yesterday's media report concerning deaths in the Acadia pimavanserin FAERS log. The analyst said based on conversations with key opinion leaders who have major experience with pimavanserin, she thinks there is unlikely a safety signal. However, she does say the concerns keep her cautious on the stock. Baral maintained her Outperform rating and $50 price target on Acadia shares, which dropped 23% to close at $16.50 yesterday.
04/10/18
JPMS
04/10/18
NO CHANGE
Target $50
JPMS
Overweight
Acadia sees little impact from CNN article, says JPMorgan
JPMorgan analyst Cory Kasimov says Acadia Pharmaceuticals management stressed to him their confidence that yesterday's CNN article would have little impact on Nuplazid's commercial prospects. Kasimov says that while management believes the news changes nothing, he worries "that the already tenuous sentiment around the name could have a difficult time withstanding this latest development." It remains to be seen what extent, if any, the creased scrutiny on the safety profile of Nuplazid negatively impacts the product's commercial outlook, Kasimov tells investors in a research note. He believes Acadia'a Q1 earnings report now has even greater significance. The analyst keeps an Overweight rating on Acadia with a $50 price target.

TODAY'S FREE FLY STORIES

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

, GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

19:35
03/24/19
03/24
19:35
03/24/19
19:35
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

NFLX

Netflix

$361.00

-17.09 (-4.52%)

AMZN

Amazon.com

$1,764.96

-53.49 (-2.94%)

AMD

AMD

$26.43

-1.47 (-5.27%)

SNE

Sony

$42.09

-1.915 (-4.35%)

GME

GameStop

$10.57

0.03 (0.28%)

MSFT

Microsoft

$117.05

-3.6 (-2.98%)

CMCSA

Comcast

$39.56

-0.49 (-1.22%)

CMCSK

Comcast

$0.00

(0.00%)

SABR

Sabre

$21.02

-0.62 (-2.87%)

MAN

Manpower

$80.83

-5.02 (-5.85%)

WBS

Webster Financial

$48.90

-3.03 (-5.83%)

NATI

National Instruments

$44.16

-1.28 (-2.82%)

JCOM

j2 Global

$84.63

-1.95 (-2.25%)

IIPR

Innovative Industrial Properties

$90.00

-0.175 (-0.19%)

CAT

Caterpillar

$129.80

-4.1 (-3.06%)

LYFT

Lyft

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 25

    Mar

  • 26

    Mar

  • 26

    Mar

  • 27

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

  • 02

    Apr

  • 04

    Apr

  • 16

    Apr

  • 18

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 29

    Apr

  • 29

    Apr

  • 10

    May

  • 12

    Jun

  • 27

    Oct

  • 29

    Mar

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

, GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

19:26
03/24/19
03/24
19:26
03/24/19
19:26
Periodicals
YouTube cancels plans for high-end dramas, comedies, Bloomberg reports »

Google-owned (GOOG;…

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

NFLX

Netflix

$361.00

-17.09 (-4.52%)

AMZN

Amazon.com

$1,764.96

-53.49 (-2.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 27

    Mar

  • 29

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

ENTG

Entegris

$34.64

-1.2 (-3.35%)

19:23
03/24/19
03/24
19:23
03/24/19
19:23
Hot Stocks
Taiwan court finds Gudeng Precision infringes Entegris' reticle pod patent »

Entegris received an oral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

MGTA

Magenta Therapeutics

$18.77

0.805 (4.48%)

19:21
03/24/19
03/24
19:21
03/24/19
19:21
Downgrade
Magenta Therapeutics rating change at Goldman Sachs »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$31.03

-0.05 (-0.16%)

, CMCSA

Comcast

$39.56

-0.49 (-1.22%)

16:20
03/24/19
03/24
16:20
03/24/19
16:20
Hot Stocks
Box Office Battle: 'Us' soars to historic $70M U.S. debut »

Comcast (CMCSA, CMCSK)…

T

AT&T

$31.03

-0.05 (-0.16%)

CMCSA

Comcast

$39.56

-0.49 (-1.22%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$42.09

-1.915 (-4.35%)

LGF.A

Lionsgate

$15.14

-0.7 (-4.42%)

DIS

Disney

$108.30

-0.36 (-0.33%)

VIAB

Viacom

$25.27

-0.7 (-2.70%)

VIA

Viacom

$30.64

-0.66 (-2.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Apr

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 07

    May

  • 08

    May

  • 20

    May

  • 06

    Jun

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

, SPX

S&P 500

$0.00

(0.00%)

16:07
03/24/19
03/24
16:07
03/24/19
16:07
Periodicals
Not enough evidence Trump obstructed justice, conspired with Russia, CNBC says »

Attorney General William…

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

, SPX

S&P 500

$0.00

(0.00%)

15:58
03/24/19
03/24
15:58
03/24/19
15:58
Periodicals
Mueller finds no Trump campaign-Russia conspiracy, Reuters reports »

Special Counsel Robert…

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASND

Ascendis Pharma

$119.21

-3.85 (-3.13%)

15:35
03/24/19
03/24
15:35
03/24/19
15:35
Hot Stocks
Ascendis Pharma announces top-line results from Phase 3 heiGHt trial »

Ascendis Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

, SPX

S&P 500

$0.00

(0.00%)

12:50
03/24/19
03/24
12:50
03/24/19
12:50
Periodicals
Trump, lawmakers awaiting details of Mueller's report, Reuters says »

U.S. lawmakers drew…

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

, SPX

S&P 500

$0.00

(0.00%)

12:44
03/24/19
03/24
12:44
03/24/19
12:44
Periodicals
China refusing to concede on U.S. demands to ease curb on tech companies,FT says »

China is refusing to…

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$175.60

-5.785 (-3.19%)

12:37
03/24/19
03/24
12:37
03/24/19
12:37
Periodicals
Alibaba acquires Israeli AR startup, Bloomberg reports »

Alibaba has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAYRY

Bayer

$0.00

(0.00%)

12:34
03/24/19
03/24
12:34
03/24/19
12:34
Periodicals
Bayer CEO says team retains backing if supervisory board, Reuters says »

Bayer's management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

AAL

American Airlines

$30.60

-0.83 (-2.64%)

, BA

Boeing

$362.15

-10.54 (-2.83%)

12:31
03/24/19
03/24
12:31
03/24/19
12:31
Periodicals
American Airlines extends Boeing 737 Max flight cancellations, Reuters says »

American Airlines (AAL)…

AAL

American Airlines

$30.60

-0.83 (-2.64%)

BA

Boeing

$362.15

-10.54 (-2.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

UBER

Uber

$0.00

(0.00%)

12:27
03/24/19
03/24
12:27
03/24/19
12:27
Periodicals
Uber to announce $3.1B deal to buy Careem, Bloomberg says »

Uber is set to announce a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDUS

Radius Health

$18.92

-0.39 (-2.02%)

12:17
03/24/19
03/24
12:17
03/24/19
12:17
Hot Stocks
Radius presents analysis from Phase 3 ACTIVE trial, data from TYMLOS studies »

Radius Health presented a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIPR

Innovative Industrial Properties

$90.00

-0.175 (-0.19%)

13:09
03/23/19
03/23
13:09
03/23/19
13:09
Periodicals
Innovative Industrial Properties flying high, Barron's says »

American cannabis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$129.80

-4.1 (-3.06%)

13:05
03/23/19
03/23
13:05
03/23/19
13:05
Periodicals
Investors missing how far Caterpillar dug into costs, Barron's says »

Caterpillar has made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

MO

Altria Group

$55.90

-0.23 (-0.41%)

12:59
03/23/19
03/23
12:59
03/23/19
12:59
Periodicals
E-cigarettes not helping people quit smoking, Barron's says »

According to the CDC,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

MAN

Manpower

$80.83

-5.02 (-5.85%)

, SABR

Sabre

$21.02

-0.62 (-2.87%)

12:51
03/23/19
03/23
12:51
03/23/19
12:51
Periodicals
Sabre, j2 Global among mid-cap stocks with sustainable dividends, Barron's says »

When it comes to…

MAN

Manpower

$80.83

-5.02 (-5.85%)

SABR

Sabre

$21.02

-0.62 (-2.87%)

WBS

Webster Financial

$48.90

-3.03 (-5.83%)

NATI

National Instruments

$44.16

-1.28 (-2.82%)

JCOM

j2 Global

$84.63

-1.95 (-2.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 18

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 10

    May

MSFT

Microsoft

$117.05

-3.6 (-2.98%)

, GME

GameStop

$10.57

0.03 (0.28%)

12:47
03/23/19
03/23
12:47
03/23/19
12:47
Periodicals
Gaming meets the cloud as investors scramble to catch up, Barron's says »

The cloud will eventually…

MSFT

Microsoft

$117.05

-3.6 (-2.98%)

GME

GameStop

$10.57

0.03 (0.28%)

AMD

AMD

$26.43

-1.47 (-5.27%)

SNE

Sony

$42.09

-1.915 (-4.35%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 29

    Mar

  • 02

    Apr

  • 04

    Apr

  • 16

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

LYFT

Lyft

$0.00

(0.00%)

12:42
03/23/19
03/23
12:42
03/23/19
12:42
Periodicals
Investors should avoid booking ride when Lyft goes public, Barron's says »

Lyft will soon be going…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

DIS

Disney

$108.30

-0.36 (-0.33%)

, AAPL

Apple

$191.11

-3.96 (-2.03%)

12:38
03/23/19
03/23
12:38
03/23/19
12:38
Periodicals
Streaming revolution too complicated, Barron's says »

The streaming revolution…

DIS

Disney

$108.30

-0.36 (-0.33%)

AAPL

Apple

$191.11

-3.96 (-2.03%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$39.56

-0.49 (-1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 11

    Apr

  • 25

    Apr

  • 08

    May

FB

Facebook

$164.25

-1.83 (-1.10%)

, GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

08:18
03/23/19
03/23
08:18
03/23/19
08:18
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$164.25

-1.83 (-1.10%)

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

TWTR

Twitter

$32.98

0.37 (1.13%)

GM

General Motors

$36.51

-0.84 (-2.25%)

AMD

AMD

$26.43

-1.47 (-5.27%)

INTC

Intel

$53.20

-1.41 (-2.58%)

MRVL

Marvell

$19.69

-1.11 (-5.34%)

MCHP

Microchip

$85.50

-1.83 (-2.10%)

MU

Micron

$41.68

-2.32 (-5.27%)

NVDA

Nvidia

$177.40

-6.52 (-3.55%)

QCOM

Qualcomm

$56.71

-1.05 (-1.82%)

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 27

    Mar

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

  • 04

    Jun

  • 05

    Jun

  • 27

    Oct

21:30
03/22/19
03/22
21:30
03/22/19
21:30
General news
Breaking General news story  »

Chicago Federal Reserve…

21:15
03/22/19
03/22
21:15
03/22/19
21:15
General news
Breaking General news story  »

Atlanta Federal Reserve…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.